Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4023610 | Journal Français d'Ophtalmologie | 2013 | 4 Pages |
Abstract
We report the case of a 31-month-old girl, treated by the ifosfamide-vincristine-actinomycin chemotherapy protocol for vaginal rhabdomyosarcoma, who developed a unilateral left ptosis on day 36Â of chemotherapy, i.e. 7Â days after the fifth vincristine dose (1.5Â mg/m2Â or 0.90Â mg). The cumulative vincristine dose was thus 4.50Â mg. The remainder of the neurological and systemic examinations were unremarkable. Laboratory testing and thoracic-cervical-cranial CT were normal. Other causes of ptosis were excluded. The ptosis decreased a few days after the infusion of vincristine and re-increased just after a new dose. It finally resolved upon lowering the dose of vincristine. According to our observations, the role of vincristine in the pathogenesis of this ptosis appears “likely”. In such cases, maintenance of treatment is possible with adjustment of vincristine doses, but requires regular follow-up.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
B. Batta, F. Trechot, V. Cloché, J.-L. George, K. Angioi,